Matches in Nanopublications for { ?s ?p "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP538461.RAe9kUk4aFnXgGecnPoXLS4faDlR9XZVVoeNLyKUOGi4k130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP538461.RAe9kUk4aFnXgGecnPoXLS4faDlR9XZVVoeNLyKUOGi4k130_provenance.
- assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP398371.RAVwTvsh3oMu2tgAy1D7YWx7hG7xqydKeYDc9wnNg7Ges130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP398371.RAVwTvsh3oMu2tgAy1D7YWx7hG7xqydKeYDc9wnNg7Ges130_provenance.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_provenance.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_provenance.
- NP350556.RAG132VleIQx4qkagMld8MfrFviLLEF6wfUu0pWf9Y2zA130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP350556.RAG132VleIQx4qkagMld8MfrFviLLEF6wfUu0pWf9Y2zA130_provenance.
- NP398372.RAwazNZkPkl5-e5dNFPtBI7wJbRqdMWA1nWdVgtBG8bJg130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP398372.RAwazNZkPkl5-e5dNFPtBI7wJbRqdMWA1nWdVgtBG8bJg130_provenance.